The role of Rho protein signaling in hypertension

Nature Reviews Cardiology

Volumn 7, Issue 11, 2010, Pages 637-647

  Loirand, Gervaise ^a   Pacaud, Pierre ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RAC1 PROTEIN; RHO FACTOR; RHO KINASE; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

BLOOD VESSEL TONE; ELECTROLYTE BALANCE; FLUID BALANCE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STROKE; VASCULAR RESISTANCE;

ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; MUSCLE, SMOOTH, VASCULAR; RAC1 GTP-BINDING PROTEIN; RHO GTP-BINDING PROTEINS; RHO-ASSOCIATED KINASES; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 78049274198     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2010.136     Document Type: Review

References (79)

1. Loirand, G., Guerin, P. & Pacaud, P. Rho kinases in cardiovascular physiology and pathophysiology. Circ. Res. 98, 322-334 (2006).
2. Zhou, Q. & Liao, J. K. Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr. Pharm. Des. 15, 3108-3115 (2009).
3. Heasman, S. J. & Ridley, A. J. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat. Rev. Mol. Cell. Biol. 9, 690-701 (2008).
4. Siehler, S. Regulation of RhoGEF proteins by G12/13-coupled receptors. Br. J. Pharmacol. 158, 41-49 (2009).
5. Schiller, M. R. Coupling receptor tyrosine kinases to Rho GTPases-GEFs what's the link. Cell Signal. 18, 1834-1843 (2006).
6. Tybulewicz, V. L. & Henderson, R. B. Rho family GTPases and their regulators in lymphocytes. Nat. Rev. Immunol. 9, 630-644 (2009).
7. Huveneers, S. & Danen, E. H. Adhesion signaling-crosstalk between integrins, Src and Rho. J. Cell Sci. 122, 1059-1069 (2009).
8. Puetz, S., Lubomirov, L. T. & Pfitzer, G. Regulation of smooth muscle contraction by small GTPases. Physiology (Bethesda) 24, 342-356 (2009).
9. Uehata, M. et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990-994 (1997).
10. Shirai, H., Autieri, M. & Eguchi, S. Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling. Curr. Opin. Nephrol. Hypertens. 16, 111-115 (2007).
11. Sanders, L. C., Matsumura, F., Bokoch, G. M. & de Lanerolle, P. Inhibition of myosin light chain kinase by p21-activated kinase. Science 283, 2083-2085 (1999).
12. Wirth, A. et al. Inhibition of contraction and myosin light chain phosphorylation in guinea-pig smooth muscle by p21-activated kinase 1. J. Physiol. 549, 489-500 (2003).
13. Foster, D. B. et al. Phosphorylation of caldesmon by p21-activated kinase. Implications for the Ca (2+) sensitivity of smooth muscle contraction. J. Biol. Chem. 275, 1959-1965 (2000).
14. Laufs, U. & Liao, J. K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273, 24266-24271 (1998).
15. Wolfrum, S. et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler. Thromb. Vasc. Biol. 24, 1842-1847 (2004).
16. Ming, X. F. et al. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 110, 3708-3714 (2004).
17. Sawada, N., Salomone, S., Kim, H. H., Kwiatkowski, D. J. & Liao, J. K. Regulation of endothelial nitric oxide synthase and postnatal angiogenesis by Racl. Circ. Res. 103, 360-368 (2008).
18. Selvakumar, B., Hess, D. T., Goldschmidt-Clermont, P. J. & Stamler, J. S. Co-regulation of constitutive nitric oxide synthases and NADPH oxidase by the small GTPase Rac. FESS Lett 582, 2195-2202 (2008).
19. 2+ sensitization of contraction in vascular smooth muscle. J. Biol. Chem. 275, 21722-21729 (2000).
20. Sauzeau, V., Sevilla, M. A., Montero, M. J. & Bustelo, X. R. The Rho/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells. J. Clin. Invest. 120, 315-330 (2010).
21. Pilowsky, P. M. & Goodchild, A. K. Baroreceptor reflex pathways and neurotransmitters: 10 years on. J. Hypertens. 20, 1675-1688 (2002).
22. Ito, K. et al. Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension. Circ. Res. 92, 1337-1343 (2003).
23. Nozoe, M. et al. Inhibition of Racl-derived reactive oxygen species in nucleus tractus solitarius decreases blood pressure and heart rate in stroke-prone spontaneously hypertensive rats. Hypertension 50, 62-68 (2007).
24. de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W. & Unger, T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52, 415-472 (2000).
25. Seko, T. et al. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ. Res. 92, 411-1418 (2003).
26. Guilluy, C. et al. The Rho exchange factor Arhgefl mediates the effects of angiotensin II on vascular tone and blood pressure. Nat. Med. 16, 183-190 (2010).
27. Jin, L. et al. Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin ll-induced hypertensive rats. J. Pharmacol. Exp. Ther. 318, 288-295 (2006).
28. Lohn, M. et al. Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension 54, 676-683 (2009).
29. Higashi, M. et al. Long-term inhibition of Rhokinase suppresses angiotensin ll-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD (P) H oxidase system. Circ. Res. 93, 767-775 (2003).
30. Kanda, T. et al. Role of Rho-kinase and p27 in angiotensin ll-induced vascular injury. Hypertension 45, 724-729 (2005).
31. Mukai, Y. et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 15, 1062-1064 (2001).
32. Ozawa, Y. & Kobori, H. Crucial role of Rho-nuclear factor-kappaB axis in angiotensin ll-induced renal injury. Am. J. Physiol. Renal. Physiol. 293, F100-F109 (2007).
33. Rossman, K. L., Der, C. J. & Sondek, J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat. Rev. Mol. Cell Biol. 6, 167-180 (2005).
34. Hilgers, R. H., Todd, J. Jr & Webb, R. C. Increased PDZ-RhoGEF/RhoA/Rho kinase signaling in small mesenteric arteries of angiotensin ll-induced hypertensive rats. J. Hypertens. 25, 1687-1697 (2007).
35. Satoh, M. et al. Requirement of Racl in the development of cardiac hypertrophy. Proc. Natl Acad. Sci. USA 103, 7432-7437 (2006).
36. Rashid, M. et al. Importance of Racl signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ. J. 73, 361-370 (2009).
37. Wassmann, S. et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Racl GTPase. Mol. Pharmacol. 59, 646-654 (2001).
38. Sawada, N., Li, Y. & Liao, J. K. Novel aspects of the roles of Racl GTPase in the cardiovascular system. Curr. Opin. Pharmacol. 10, 116-121 (2010).
39. Vecchione, C. et al. Pressure-induced vascular oxidative stress is mediated through activation of integrin-linked kinase 1/betaPIX/Rac-l pathway. Hypertension 54, 1028-1034 (2009).
40. Zimmerman, M. C., Lazartigues, E., Sharma, R. V. & Davisson, R. L. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ. Res. 95, 210-216 (2004).
41. Zimmerman, M. C. et al. Requirement for Racldependent NADPH oxidase in the cardiovascular and dipsogenic actions of angiotensin II in the brain. Circ. Res. 95, 532-539 (2004).
42. Sagara, Y. et al. Pressor response induced by central angiotensin II is mediated by activation of Rho/Rho-kinase pathway via AT1 receptors. J. Hypertens. 25, 399-406 (2007).
43. Seasholtz, T. M. et al. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27 (Kip1) expression in the vasculature of hypertensive rats. Circ. Res. 89, 488-495 (2001).
44. Ni, W. et al. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ. Res. 89, 415-421 (2001).
45. Kataoka, C. et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 39, 245-250 (2002).
46. Williams, J., Bogwu, J. & Oyekan, A. The role of the RhoA/Rho-kinase signaling pathway in renal vascular reactivity in endothelial nitric oxide synthase null mice. J. Hypertens. 24, 1429-1436 (2006).
47. Ito, K. et al. Rho/Rho-kinase pathway in the brainstem contributes to hypertension caused by chronic nitric oxide synthase inhibition. Hypertension 43, 156-162 (2004).
48. Denniss, S. G., Jeffery, A. J. & Rush, J. W. RhoA-Rho kinase signaling mediates endothelium-and endoperoxide-dependent contractile activities characteristic of hypertensive vascular dysfunction. Am. J. Physiol. Heart Circ. Physiol. 298, H1391-H1405 (2010).
49. Moriki, N. et al. RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hypertens. Res. 27, 263-270 (2004).
50. Ying, Z., Jin, L., Dorrance, A. M. & Webb, R. C. Increaseed expression of mRNA for regulator of G protein signaling domain-containing Rho guanine nucleotide exchange factors in aorta from stroke-prone spontaneously hypertensive rats. Am. J. Hypertens. 17, 981-985 (2004).
51. Bian, Y. L. et al. Aproteomic analysis of aorta from spontaneously hypertensive rat: RhoGDI alpha upregulation by angiotensin ll via AT (1) receptor. Eur. J. Cell. Biol. 87, 101-110 (2008).
52. Kumai, T. et al. Fasudil attenuates sympathetic nervous activity in the adrenal medulla of spontaneously hypertensive rats. Life Sci. 81, 1193-1198 (2007).
53. Ito, K. et al. Inhibition of rho-kinase in the nucleus tractus solitarius enhances glutamate sensitivity in rats. Hypertension 46, 360-365 (2005).
54. Ito, K., Hirooka, Y., Kimura, Y., Shimokawa, H. & Takeshita, A. Effects of hydroxyfasudil administered to the nucleus tractus solitarii on blood pressure and heart rate in spontaneously hypertensive rats. Clin. Exp. Hypertens. 27, 269-277 (2005).
55. Ishimaru, K. et al. Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats. J. Cardiovasc. Pharmacol. 50, 187-194 (2007).
56. Weber, D. S. & Webb, R. C. Enhanced relaxation to the rho-kinase inhibitor Y-27632 in mesenteric arteries from mineralocorticoid hypertensive rats. Pharmacology 63, 129-133 (2001).
57. Wehrwein, E. A., Northcott, C. A., Loberg, R. D. & Watts, S. W. Rho/Rho kinase and phosphoinositide 3-kinase are parallel pathways in the development of spontaneous arterial tone in deoxycorticosterone acetate-salt hypertension. J. Pharmacol. Exp. Ther. 309, 1011-1019 (2004).
58. Wirth, A. et al. G12-G13-LARG-mediated signaling in vascular smooth muscle is required for saltinduced hypertension. Nat Med. 14, 64-68 (2008).
59. Benter, I. F., Canatan, H., Benboubetra, M., Yousif, M. H. & Akhtar, S. Global upregulation of gene expression associated with renal dysfunction in DOCA-salt-induced hypertensive rats occurs via signaling cascades involving epidermal growth factor receptor: a microarray analysis. Vascul. Pharmacol. 51, 101-109 (2009).
60. Ishikawa, Y. et al. Long-term administration of rhokinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension 47, 1075-1083 (2006).
61. Sun, G. P. et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J. Am. Soc. Nephrol. 17, 2193-2201 (2006).
62. Diah, S. et al. Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells. Exp. Cell Res. 314, 3654-3662 (2008).
63. Fujita, T. Mineralocorticoid receptors, saltsensitive hypertension, and metabolic syndrome. Hypertension 55, 813-818 (2010).
64. Shibata, S. et al. Modification of mineralocorticoid receptor function by Racl GTPase: implication in proteinuric kidney disease. Nat. Med. 14, 1370-1376 (2008).
65. Rikitake, Y. et al. Decreased perivascular fibrosis but not cardiac hypertrophy in R0CK1± haploinsufficient mice. Circulation 112, 2959-2965 (2005).
66. Zhang, Y. M. et al. Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. FASEB J. 20, 916-925 (2006).
67. Thumkeo, D. et al. Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol. Cell. Biol. 23, 5043-5055 (2003).
68. Sauzeau, V., Jerkic, M., Lopez-Novoa, J. M. & Bustelom, X. R. Loss of Vav2 proto-oncogene causes tachycardia and cardiovascular disease in mice. Mol. Biol. Cell 18, 943-952 (2007).
69. Sauzeau, V. et al. Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction. Nat. Med. 12, 841-845 (2006).
70. Hassanain, H. H. et al. Hypertension caused by transgenic overexpression of Racl. Antioxid. Redox Signal. 9, 91-100 (2007).
71. Masumoto, A. et al. Possible involvement of Rhokinase in the pathogenesis of hypertension in humans. Hypertension 38, 1307-1310 (2001).
72. Kishi, T. et al. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 111, 2741-2747 (2005).
73. Noma, K. et al. Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J. Am. Coll. Cardiol. 49, 698-705 (2007).
74. Seasholtz, T. M. et al. Rho kinase polymorphism influences blood pressure and systemic vascular resistance in human twins: role of heredity. Hypertension 47, 937-947 (2006).
75. Rankinen, T. et al. Amajor haplotype block at the rho-associated kinase 2 locus is associated with a lower risk of hypertension in a recessive manner: the HYPGENE study. Hypertens. Res. 31, 1651-1657 (2008).
76. Oka, M., Fagan, K. A., Jones, P. L. & McMurtry, I. F. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br. J. Pharmacol. 155, 444-454 (2008).
77. Fukumoto, Y. et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91, 391-392 (2005).
78. Fujita, H. et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 25, 144-149 (2010).
79. Guilluy, C. et al. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am. J. Respir. Crit. Care Med. 179, 1151-1158 (2009).